Bona fide gift to Jon Stonehouse of 20000 shares of BioCryst Pharmaceuticals subject to Section 16
| BCRX Stock | USD 7.50 0.01 0.13% |
Slightly above 53% of BioCryst Pharmaceuticals' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that some traders are interested. BioCryst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BioCryst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
BioCryst |
Filed transaction by Biocryst Pharmaceuticals director. Exempt bona fide gift subject to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
BioCryst Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the BioCryst Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
BioCryst Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BioCryst Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioCryst Pharmaceuticals Fundamental Analysis
We analyze BioCryst Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
BioCryst Pharmaceuticals is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
BioCryst Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioCryst Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
BioCryst Pharmaceuticals Related Equities
| XFOR | X4 Pharmaceuticals | 11.26 | ||||
| IMUX | Immunic | 5.26 | ||||
| APLS | Apellis Pharmaceuticals | 4.63 | ||||
| MCRB | Seres Therapeutics | 4.55 | ||||
| SAVA | Cassava Sciences | 3.92 | ||||
| AXSM | Axsome Therapeutics | 2.70 | ||||
| TGTX | TG Therapeutics | 2.16 | ||||
| VKTX | Viking Therapeutics | 2.04 | ||||
| PDSB | PDS Biotechnology | 1.90 | ||||
| DAWN | Day One | 1.33 | ||||
| BPMC | Blueprint Medicines | 0.50 | ||||
| INMB | INmune Bio | 0.20 | ||||
| AVXL | Anavex Life | 0.11 | ||||
| KZR | Kezar Life | 0.40 | ||||
| ATRA | Atara Biotherapeutics | 0.65 | ||||
| PIRS | Pieris Pharmaceuticals | 1.41 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.57 | ||||
| CGTX | Cognition Therapeutics | 2.44 | ||||
| BIVI | Biovie | 3.90 |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.